Clinical Trial Search

Primary: Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F…

Primary: Geometric Mean Titers (GMTs) of Antibodies Against Pandemrix Vaccine Strain — 309.8; 227.5 titer

Primary: Geometric Mean Titers (GMTs) of Vaccine Serogroups Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination…

Primary: Apathy — 88.91; 95.64 T-score — p=0.181

Primary: Changes in Gastrointestinal Symptom Severity and Health Related Quality of Life — 2.88; 2.10 Scores on a Scale

Primary: Subject Success (Success is Defined Only if All of These Criteria Are Fulfilled) — 0; 0 Subjects

Primary: Change in Visceral Adipose Tissue Area Measured by Computed Tomography. — -1.5; 2.8 cm2

Primary: Continuous Abstinence From Smoking at Ten Weeks Post-quit — 31; 21; 17; 26 participants

Primary: Metabolite Associated With Inflammation (Cadaverine) — 1.119186; 0.92077 ion count — p=<0.05

Primary: Progression-Free Survival (PFS) — 8.6; 8.3; 8.2; 6.9 months — p=0.2651

Primary: Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter…

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months — 49.2; 47.4; 48.1; 0.8 Units on a scale — p=<0.0001

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months — 54.7; 56.0; 53.0; 7.3 Units on a scale — p=<0.0001

Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001

Primary: Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity — 3.03; 2.73; 2.84; 2.83 Scores on a scale